Ovarian Cancer Clinical Trial Breakthroughs and Impact on Management

被引：12

作者：

Previs, Rebecca Ann ^{[1
]}

Secord, Angeles Alvarez ^{[1
]}

机构：

[1] Duke Univ, Duke Canc Inst, Dept Obstet & Gynecol, Div Gynecol Oncol,Med Ctr, Box 3079, Durham, NC 27710 USA

来源：

OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA | 2019年 / 46卷 / 01期

关键词：

Ovarian cancer; Clinical trials; Cytoreduction; PARP inhibitor; Bevacizumab; Immunotherapy; RECURRENT EPITHELIAL OVARIAN; OLAPARIB MAINTENANCE THERAPY; PRIMARY PERITONEAL CANCER; PACLITAXEL PLUS CARBOPLATIN; PHASE-III TRIAL; OPEN-LABEL; DOUBLE-BLIND; NEOADJUVANT CHEMOTHERAPY; FALLOPIAN-TUBE; 1ST-LINE CHEMOTHERAPY;

D O I：

10.1016/j.ogc.2018.09.005

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Ovarian cancer treatment continues to evolve. Despite aggressive surgery and chemotherapy, most women will ultimately die from disease. Improvement in disease control are due to the incorporation of molecular targeted agents and the adoption of maintenance therapy. Maintenance therapy has been shown to enhance progression-free survival. Recent surgical trials have evaluated the role of neoadjuvant chemotherapy versus primary debulking at the time of diagnosis in advanced stage ovarian cancer. The role of lymph node dissection and secondary cytoreductive surgeries have also been evaluated. This article reviews contemporary trials of maintenance therapy and novel drug development.

引用

页码：67 / +

页数：23

共 50 条

[31] Minute variation in murine ovarian cancer preclinical models significantly impact immunotherapy results obtained for clinical trial
Mcgray, A. J. Robert
Starbuck, Kristen
Masoumi-Moghaddam, Samar
Francois, Ariel
Odunsi, Kunle
Zsiros, Emese
CANCER RESEARCH, 2017, 77
[32] THE IMPACT OF SUBSPECIALTY TRAINING ON THE MANAGEMENT OF ADVANCED OVARIAN-CANCER
EISENKOP, SM
SPIRTOS, NM
MONTAG, TW
NALICK, RH
WANG, HJ
GYNECOLOGIC ONCOLOGY, 1992, 47 (02) : 203 - 209
[33] Impact of a Clinical Trial Initiative on Clinical Trial Enrollment in a Multidisciplinary Prostate Cancer Clinic
Madsen, Lydia T.
Kuban, Deborah A.
Choi, Seungtaek
Davis, John W.
Kim, Jeri
Lee, Andrew K.
Domain, Debora
Levy, Larry
Pisters, Louis L.
Pettaway, Curtis A.
Ward, John F.
Logothetis, Christopher
Hoffman, Karen E.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (07): : 993 - 998
[34] Impact of Cancer Therapy on the Ovarian Function and Fertility Preserving Management
Metindir, Jale
Bozkurt, Ceyhun
JOURNAL OF THE TURKISH-GERMAN GYNECOLOGICAL ASSOCIATION, 2005, 6 : 23 - 29
[35] Genetic testing in ovarian cancer - clinical impact and current practices
Knabben, Laura
Imboden, Sara
Mueller, Michel D.
HORMONE MOLECULAR BIOLOGY AND CLINICAL INVESTIGATION, 2020, 41 (03)
[36] The clinical impact of intra- and extracellular miRNAs in ovarian cancer
Yoshida, Kosuke
Yokoi, Akira
Kato, Tomoyasu
Ochiya, Takahiro
Yamamoto, Yusuke
CANCER SCIENCE, 2020, 111 (10) : 3435 - 3444
[37] Safety and management of niraparib monotherapy in ovarian cancer clinical trials
Monk, Bradley J.
Gonzalez-Martin, Antonio
Buckley, Lynn
Matulonis, Ursula A.
Rimel, B. J.
Wu, Xiaohua
Moore, Kathleen N.
Mirza, Mansoor R.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (06) : 971 - 981
[38] Sarcopenia: Clinical implications in ovarian cancer, diagnosis, etiology, and management
Seol, Aeran
Kim, Se Ik
Song, Yong Sang
SPORTS MEDICINE AND HEALTH SCIENCE, 2020, 2 (04) : 202 - 210
[39] Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management
Mandai, Masaki
Yamaguchi, Ken
Matsumura, Noriomi
Baba, Tsukasa
Konishi, Ikuo
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (05) : 383 - 391
[40] The role of gene expression profiling in the clinical management of ovarian cancer
Olivier, R. I.
van Beurden, M.
van't Veer, L. J.
EUROPEAN JOURNAL OF CANCER, 2006, 42 (17) : 2930 - 2938

← 1 2 3 4 5 →